• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Vertex shares downgraded at Oppenheimer amid LSR trial uncertainties

by December 19, 2024
written by December 19, 2024

Investing.com — Oppenheimer on Thursday downgraded Vertex Pharmaceuticals (NASDAQ:VRTX) after reporting Phase 2 trial results for suzetrigine in the treatment of painful lumbosacral radiculopathy (LSR).

Suzetrigine showed a significant pain reduction in the trial, but failed to outperform the placebo, leading to questions about its efficacy.

As a result of these uncertainties and the ambiguous benefit/risk profile of suzetrigine in LSR, the stock rating for Vertex has been downgraded to Perform from Outperform at Oppenheimer. The price target has also been removed, previously set at $540.

Despite the drug demonstrating a favorable safety profile, with lower adverse event rates compared to placebo, the lack of clear efficacy has impacted its perceived benefit/risk profile and commercial potential.

The Phase 2 results indicated a mean reduction of 2.02 points in the Numeric Pain Rating Scale (NPRS) for patients treated with suzetrigine. However, the placebo group experienced a nearly identical reduction of 1.98 points, showing no significant separation between the two groups.

This similarity in outcomes has cast doubt on the drug’s effectiveness, despite Vertex’s plans to move forward with a Phase 3 program, pending discussions with the FDA.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
States, environmental groups drop lawsuit over US Postal Service EV purchase plans
next post
Kinder Morgan subsidiary moves forward with $1.4b Mississippi Crossing Project

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025
    • This California startup is cleaning water and removing CO₂ from the atmosphere — all at a reduced cost

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (504)
    • Stock (6,426)

    Latest News

    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

    Popular News

    • Column-Forget bond vigilantes, watch the currency cops :Mike Dolan
    • Swiss National Bank Chairman wary of cryptocurrencies

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy